Global Infectious Disease Drug Market Size, Share and Forecast 2019-2025Posted by nabeel on January 30th, 2021 The global infectious disease drug market is projected to grow at a CAGR of over 4% during the forecast period. Infectious diseases transfer from person to person, and bites of insects and animals, through ingestion of contaminated food or water or being exposed to organisms such as bacteria, viruses, parasites, and fungi in the surroundings. The factors that are supporting the growth of the infectious disease drug industry include the increased prevalence of diseases and continuous contributions by the key players in the global infectious diseases drug market. Get Free Sample Copy @ https://www.omrglobal.com/request-sample/infectious-disease-drug-market Some of the key players operating in the market across the globe include Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA, among others. These key players are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others to sustain in a competitive environment and gain maximum share in the global infectious disease drug market. In November 2019, Allergan Plc announced the achievement of the Qualified Infectious Disease Product (QIDP) designation and Fast Track Designation for ATM-AVI by the US FDA for the treatment of various infectious diseases, such as ventilator-associated bacterial pneumonia (VABP)/ hospital-acquired bacterial pneumonia (HABP), complicated intra-abdominal infections (cIAI), and complicated urinary tract infections (cUTI). In November 2019, Bayer AG expanded the 5-year collaboration with the World Health Organization (WHO) for the R&D activities on the infectious disease such as taeniasis and neurocystercosis, which are the major preventable cause of epilepsy. In May 2019, Celegen Corp. announced that it has received the Breakthrough Therapy designation to POMALYST (pomalidomide) from the US FDA for the treatment of HIV patients. In June 2018, Gilead Sciences Inc. and Hookipa partnered and signed a licensing agreement for the development of immunotherapies against HIV and Hepatitis B. Through this agreement both the companies together manufacture arenavirus-based vectors for clinical development by Gilead Sciences Inc. Current Market Trends Covered in the Global Infectious Disease Drug Market Report:
Global Infectious Disease Drug Market - Segmentation By Disease Type
By Treatment Type
Global Infectious Disease Drug Market – Segmentation by Region North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buying From us – 1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation. 4. Our expert research analysts answer all your questions before and after purchasing your report. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/infectious-disease-drug-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404 Like it? Share it! More by this author |